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Background: In-hospital hypovitaminosis C is highly prevalent but almost completely unrecognized. Medical awareness
of this potentially important disorder is hindered by the inability of most hospital laboratories to determine
plasma vitamin C concentrations. The availability of a simple, reliable method for analyzing plasma vitamin C could
increase opportunities for routine plasma vitamin C analysis in clinical medicine.
Methods: Plasma vitamin C can be analyzed by high performance liquid chromatography (HPLC) with electrochemical
(EC) or ultraviolet (UV) light detection. We modified existing UV-HPLC methods for plasma total vitamin C analysis
(the sum of ascorbic and dehydroascorbic acid) to develop a simple, constant-low-pH sample reduction
procedure followed by isocratic reverse-phase HPLC separation using a purely aqueous low-pH non-buffered
mobile phase. Although EC-HPLC is widely recommended over UV-HPLC for plasma total vitamin C analysis, the
two methods have never been directly compared. We formally compared the simplified UV-HPLC method with
EC-HPLC in 80 consecutive clinical samples.
Results: The simplified UV-HPLC method was less expensive, easier to set up, required fewer reagents and no
pH adjustments, and demonstrated greater sample stability than many existing methods for plasma vitamin C
analysis. When compared with the gold-standard EC-HPLC method in 80 consecutive clinical samples exhibiting
a wide range of plasma vitamin C concentrations, it performed equivalently.
Conclusion: The easy set up, simplicity and sensitivity of the plasma vitamin C analysis method described here
could make it practical in a normally equipped hospital laboratory. Unlike any prior UV-HPLC method for plasma total
vitamin C analysis, it was rigorously compared with the gold-standard EC-HPLC method and performed equivalently.
Adoption of this method could increase the availability of plasma vitamin C analysis in clinical medicine.
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The disease of terminal vitamin C deficiency – scurvy –
is first suspected on clinical grounds. The diagnosis is
confirmed by documenting a plasma vitamin C concen-
tration < 11.4 μmol/L and observing prompt clinical im-
provement after appropriate vitamin C provision [1, 2].
Scurvy is rare in the modern world, but hypovitamino-
sis C (plasma vitamin C concentration < 28.4 μmol/L
[3]) or marginal vitamin C deficiency (plasma vitamin C* Correspondence: l.hoffer@mcgill.ca
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Hypovitaminosis C occurs in ~ 10 % of the general popula-
tion [4], in ~ 30 % of cigarette smokers [5, 6] and ~ 60 % of
acutely hospitalized patients [7–14], in whom it could
contribute to fatigue and mood disturbance [13–15], im-
mune system dysfunction [7, 16, 17], impaired wound
healing [18–20], the complex regional pain syndrome
[21] and the complications of cardiovascular disease
[22–26].
Vitamin C distributes rapidly throughout the body’s extra-
cellular fluids. Systemic inflammation and intravenous fluid
therapy increase the body’s extracellular fluid volume,
with resultant lowering of the concentration of vitaminis article is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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C is not solely a phenomenon of extravascular redistribu-
tion, however [12, 29, 30]. Systemic inflammation ignites an
oxidative process that accelerates cellular vitamin C uptake
and catabolism and increases its nutritional requirement
[31–33]. The best-studied human example of this
phenomenon is cigarette smoking [20, 34, 35], which accel-
erates vitamin C catabolism [35], lowers its plasma and tis-
sue concentrations [36, 37] and increases its nutritional
requirement [6, 34]. The depleted plasma vitamin C con-
centration of cigarette smokers can be re-normalized either
by smoking cessation [38] or vitamin C supplementation
[34], both of which decrease circulating concentrations of
the biomarkers of oxidative stress [39, 40]. Acutely hospi-
talized patients experience inflammatory-oxidative stresses
that are much greater than the stress caused by cigarette
smoke. A combined history of inadequate vitamin C intake
and systemic inflammation strongly predicts hypovitami-
nosis C [10, 11, 41, 42].
The high prevalence, potentially serious adverse conse-
quences and easy preventability of in-hospital hypovitami-
nosis C would normally motivate vigorous investigation of
its clinical implications, especially since small randomized
clinical trials of vitamin C supplementation in vitamin C-
deficient patients suggest clinical benefit [7, 14, 43]. How-
ever, much greater physician awareness and many more
clinical trials would be required to change the current bias
of medical practice, which is to avoid prescribing vitamin
C supplements even to patients whose dietary intake is in-
adequate and who are likely to be vitamin C-deficient.
It is a barrier to medical awareness of in-hospital
hypovitaminosis C that very few clinical laboratories are
equipped to detect it. Shipment of samples to reference
laboratories is problematic because vitamin C is notori-
ously unstable, requiring rapid plasma stabilization and
continuous storage at -80o C [44, 45]. We attempted to
surmount this barrier by developing a simple, accurate,
robust and inexpensive plasma vitamin C method that
could easily be set up and taken down in any normally
equipped clinical laboratory.
The most sensitive and selective method for plasma
vitamin C analysis uses high-pressure liquid chromatog-
raphy (HPLC) coupled to an electrochemical (EC)
detector [46–57]. EC-HPLC is invaluable in the research
laboratory, but it requires costly, dedicated, high-
maintenance equipment operated by specifically trained
technicians. HPLC methods that require only an ordinary
UV light detector are available [49, 51, 52, 56, 58–68] but
their practicality in a non-specialized clinical laboratory is
limited by a variety of characteristics: complicated mobile
phase compositions with appreciable preparation and col-
umn conditioning times, dedicated columns, and compli-
cated procedures to reduce dehydroascorbic acid to
ascorbic acid in order to analyze total vitamin C, orinability to measure total vitamin C at all. Vitamin C con-
sists of ascorbic acid and its redox partner, dehydroascor-
bic acid. The generic terms are used here, acknowledging
that at physiological pH ascorbic acid is almost completely
ionized and hence more correctly termed ascorbate (see
Fig. 1). We incorporated recent improvements in food
vitamin C analysis [69, 70] to develop a streamlined UV-
HPLC plasma vitamin C analysis that is simple, sensitive
and accurate enough for use in any normally equipped
clinical laboratory.
EC-HPLC is commonly recommended as the method of
choice for plasma vitamin C analysis [46, 49, 51, 56, 57],
but no direct comparison of EC-HPLC and UV-HPLC
methods for plasma total vitamin C have been re-
ported. We therefore formally compared the simplified
UV-HPLC method with EC-HPLC in 80 consecutive clin-
ical samples.
Methods
Sample acquisition, handling, and storage
Venous blood (4 mL) was drawn into a 4 mL K2EDTA
Vacutainer tube, mixed and immediately pushed into
crushed ice and delivered to the laboratory for process-
ing within one hour, as previously described [13, 14].
The plasma was separated in a refrigerated centrifuge
(4o C, 8 min, 2740 g) after which 0.2–0.4 mL of the
resulting supernatant was immediately added to an equal
volume of 10 % (w/v) metaphosphoric acid (MPA) in
2 mmol/L disodium EDTA, left on ice for 5 min, and
cold-centrifuged (4o C, 10 min, 16,000 g) as described by
Lykkesfeldt [55]. The resulting protein-free acid super-
natant was immediately flash-frozen in dry ice/ethanol
and stored continuously at -80o C until analysis either
by EC- or UV-HPLC.
EC-HPLC
The EC-HPLC method used to analyze ascorbic acid
was closely similar to that of Levine, Wang and Rumsey
[53]. Total vitamin C was analyzed using the sample re-
duction procedure described by Lykkesfedlt [54, 55]. We
have used these reliable methods in our research labora-
tory for several years [13, 14, 71].
The analytical system consisted of an Agilent 1100
series HPLC system equipped with a Coulochem III
electrochemical detector (ESA Inc) and a 5011A analyt-
ical cell. Electrode 1 was set to -175 mV, detector range
500 nA, and electrode 2 was set at 550 mV, detection
range 50 μA. The HPLC column was a reverse phase
Phenomenex Luna (4.6 x 250 mm, 5 μm) preceded by a
SecurityGuard C18 cartridge. Column temperature was
maintained at 25o C. The mobile phase consisted of
25 % methanol and 75 % water containing 0.05 mol/L
monobasic sodium phosphate, 0.05 mol/L sodium acet-
ate trihydrate, 189 μmol/L dodecyltrimethylammonium
Fig. 1 Vitamin C metabolism. Ascorbic acid participates both in acid-base (ascorbic acid-ascorbate, pK 4.2) and oxidoreduction reactions (ascorbate-
dehydroascorbic acid). The latter reaction involves transient creation of the ascorbyl radical (not shown). Vitamin C (or total vitamin C) refers to the
sum of ascorbic acid, ascorbate and dehydroascorbic acid. Under the strongly reducing, neutral pH conditions in the bloodstream, almost all vitamin C
circulates as ascorbate. As soon as the blood cells are removed from plasma, ascorbate progressively oxidizes to dehydroascorbic acid, which is highly
prone to irreversible hydrolysis to 2,3-diketogulonic acid. Diketogulonic acid is oxidized to smaller molecules, including oxalate, which are excreted in
the urine. In order to minimize loss of vitamin C, freshly obtained plasma must immediately be acid-deproteinized and flash frozen, and strongly acidic
conditions maintained as much as possible throughout sample storage and processing
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adjusted to pH 4.8 using orthophosphoric acid. The flow
rate was 0.8 ml/min (isocratic). Retention times varied
between 6 and 8 min depending on the extent of column
conditioning. At the time of analysis, acidic protein-free
plasma samples were thawed on ice in dim light and
processed in two aliquots. To measure ascorbic acid,
50 μL of sample was mixed with 200 μL of water. The
analysis of total vitamin C (ascorbic acid plus dehydroas-
corbic acid) required a reduction reaction in which
50 μL of sample was mixed with 25 μL of 2.5 mmol/L
tris(2-carboxy ethyl) phosphine hydrochloride (TCEP) in
800 mmol/L TRIS buffer (pH 9) and allowed to stand in
the dark for 5 min, after which 175 μL McIlvaine buffer
(0.28 mol/L citric acid in 0.56 mol/L dibasic sodium
phosphate, pH 4.5) was added. Both aliquots were cen-
trifuged (4o C, 5 min, 16,000 g) and the supernatants
kept on ice and manually injected (20 μL) into the
HPLC. At the end of each day’s sample run, the system
was flushed with 25 % methanol in water in order to
elute the buffers, but not so extensively as to affect ion-
pairing conditions and alter analyte retention times.The HPLC column required regeneration at 3–4
month intervals. The EC device was passivated with
strong acid at 6–12 month intervals. These procedures
required re-equilibration of the column and system, a
process lasting a day or longer.
UV-HPLC
The analysis was carried out using a Waters 2695 Separa-
tions Module equipped with a Waters 2487 dual wave-
length UV detector set to 245 nm. The column was a
reverse phase Agilent Zorbax Eclipse XDB-C18 (4.6 x
150 mm, 3.5 μm) fitted with an Agilent Eclipse XDB-C18
guard column. The column temperature was maintained
at 25o C. The mobile phase consisted of 1.8 mmol/L sul-
furic acid (pH 2.7). The flow rate was 0.8 mL/min. The re-
tention time was 3 min. There was a 7 min delay between
injections to allow the uric acid peak to elute (5–6 min).
Zero-degree thawed samples were divided into two
aliquots of 30 μL in 0.6 mL plastic Eppendorf tubes. To
measure total vitamin C, an equal volume of 5 mmol/L
TCEP in water (pH 2) was added and the sample allowed
to react for 20 min at room temperature in the dark. To
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added instead of TCEP and the sample kept on ice. Both
samples were then centrifuged (4o C, 5 min, 16,000 g) and
the supernatants kept on ice and transferred to autoinjec-
tion vials and either injected immediately onto the HPLC
column (injection volume 20 μL) or kept in the refriger-
ated auto-sampler for up to 4 h. At the end of the day’s
sample run, the system was rinsed with 40 % acetonitrile
in water to remove the acidic mobile phase and any po-
tential sample contaminants. Figure 2 summarizes the
sample procedure for total vitamin C analysis.
For both methods, a standard curve was developed by
using a peak areas linear regression equation from six
ascorbic acid standards made up in MPA/EDTA ranging
in concentration from 0 to 100 μmol/L. Each sample
run included a plasma quality control sample.Patients
The UV-HPLC and EC-HPLC methods were used to analyze
ascorbic acid and total vitamin C in plasma samples obtainedFig. 2 Sample preparation for plasma total vitamin C analysis by UV-HPLC.from 80 consecutive clinical samples from patients attending
an out-patient oncology clinic and enrolled in a study to
evaluate their nutritional status. The protocol for that study
was approved by the Research Ethics Committee of the
Jewish General Hospital (clinicaltrials.gov registration
#NCT01631526); its results will be reported separately.Statistical analysis
Statistical analyses were performed using Graph Pad
Prism Version 5.01.Results
Validation of the UV-HPLC method
A range of TCEP concentrations and reaction times was
tested to verify the effectiveness of the sample reduction
procedure described above, namely, 20 min incubation
using 5 mmol/L TCEP at pH 2. Extension of the TCEP
incubation period to 40 min left the results unchanged.
The UV absorbance signal was linear both within the
usual physiological range (5–100 μmol/L) and higherThe individual steps are described in detail in the text
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logical range (addition of 25 and 50 μmol/L known ascor-
bic acid to plasma samples with a concentration of
37 μmol/L) yielded total vitamin C recoveries of 106 %
and 100 % respectively. The identity and specificity of the
ascorbic acid chromatographic peak was verified by treat-
ing plasma samples with ascorbate oxidase and document-
ing complete disappearance of the ascorbic acid peak
without any other change in the chromatogram.
The stability of MPA-stabilized samples (for the ascor-
bic acid measurement) and TCEP-reduced MPA-
stabilized samples (for the total vitamin C measurement)
were assessed by allowing them to remain in the HPLC
autosampler at 4o C for up to 4 h prior to on-column in-
jection (samples are normally injected within one hour).
The ascorbic acid signal for un-reduced samples (ascor-
bic acid) decreased by 3–6 % after 4 h in the autosam-
pler, whereas the signal for TCEP-reduced samples (total
vitamin C) remained unchanged for at least 5 h. Figure 3
illustrates a typical UV-HPLC-derived chromatogram.
Comparison of EC-HPLC and UV-HPLC methods
A control plasma sample was re-analyzed on 10 different
days, yielding coefficients of variation for the EC and
UV methods of 4.5 % and 3.3 %, respectively (for total
vitamin C analysis) and 5.3 % and 4.4 %, respectively (for
ascorbic acid analysis). The concentrations (mean ± SD)
were as follows: ascorbic acid 104 ± 5.5 μmol/L by EC-
HPLC and 107 ± 4.7 μmol/L by UV-HPLC; total vitamin
C 106 ± 4.8 μmol/L by EC-HPLC and 110 ± 3.7 μmol/L
by UV-HPLC. The lower limit of signal quantization was
1.34 μmol/L with EC-HPLC and < 4.0 μmol/L with UV-
HPLC.
As shown in Table 1, plasma ascorbic acid and total
vitamin C concentrations in 80 consecutive clinical sam-
ples determined by both methods ranged from 4–Fig. 3 High-pressure liquid chromatogram (measured in UV absorbance un
concentration was 10.7 μmol/L. The ascorbic acid peak eluted 3.1 min after
reagents metaphosphoric acid and EDTA, respectively134 μmol/L; the individual values were highly correlated
(Spearman r = 0.96, P < 0.0001 both for ascorbic acid and
total vitamin C). The Deming regression graph for total
vitamin C is shown in Fig. 4. The 95 % confidence inter-
val for the slope of the regression equation encompassed
1 (0.99–1.12) and the corresponding interval for the Y-
intercept encompassed zero (-2.15–4.49), indicating that
the concentrations reported by the different methods
were equal and indistinguishable. There was similarly
close agreement for the ascorbic acid analysis.
Even a very high correlation does not, in itself, provide
sufficient evidence of acceptable agreement between two
methods, so a Bland-Altman analysis was carried out to
quantify any systematic difference between the two
methods [72]. The resulting Bland-Altman plot is shown
in Fig. 5. The mean difference (bias) between the EC
and UV results was -3.70 μmol/L. Bland-Altman plots
are generally interpreted informally and in the context
of their clinical significance. For total vitamin C concen-
trations < 28.4 μmol/L, which represented 24 % of the
sample and are the ones of most clinical interest, the
bias between the methods was -1.02 μmol/L (not signifi-
cantly different from zero).
Table 2 compares EC-HPLC as used in our laboratory,
the three available UV-HPLC methods [59, 63, 64] for
total vitamin C, and the UV-HPLC method described
here regarding its use in an ordinary clinical laboratory.Discussion
UV-HPLC analysis of vitamin C in biological fluids is
not novel as a general procedure: it was first reported
more than 40 years ago [73] and many variations have
subsequently been published [49, 51, 52, 56, 58, 60–67].
However, a variety of methodological complexities and
the inability, in all but a few of them [59, 63, 64], toits) derived from a plasma sample in which the total vitamin C
injection onto the column. The two earlier peaks are due to the
Table 1 Plasma ascorbic acid and total vitamin C concentrations (μmol/L) as measured by EC-HPLC and UV-HPLC in 80 consecutive
patient samples
EC-HPLC UV-HPLC
Ascorbic acid Mean ± SD 39.1 ± 24.3 45.2 ± 27.6
Median (interquartile range) 35.3 (17.1-53.5) 38.1 (25.0-60.0)
Range 5.80-117 4.10-134
Total vitamin C Mean ± SD 43.3 ± 26.3 47.0 ± 27.8
Median (interquartile range) 39.0 (20.0-59.9) 40.0 (26.5-63.3)
Range 5 - 126 4 - 133
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C, limit their usefulness in the clinical setting.
Total plasma vitamin C is the measurement of choice
for two reasons: first, it indicates the total amount of
vitamin C in the sample, and second, ascorbic acid can
easily oxidize to dehydroascorbic acid in a busy clinical
setting due to inadvertent and sometimes unavoidable
delays or minor technical shortcomings in sample hand-
ling or the analysis procedure. Indeed, there is some evi-
dence that much or most dehydroascorbic acid detected
in plasma may be artificially generated during sample
handling and processing [49, 74]. Treatment of samples
with an appropriate reducing agent helps prevent under-
estimation of vitamin C concentrations (and hence over-
diagnosis of hypovitaminosis C) due to minor vagaries
in sample handling and processing [75]. It is a major ad-
vantage of the present method that the sample reduction
procedure is extremely simple and trouble-free.
The UV-HPLC method described here for plasma ascor-
bic acid and total vitamin C analysis demonstrates highly
acceptable sensitivity and reproducibility. It is especially
notable for easy and rapid setup, analytical column condi-
tioning, fewer reagents and sample manipulations than
other comparable methods, and a very simple constant-Fig. 4 Correlation between the electrochemical (EC) and ultraviolet
(UV) detection methods in 80 consecutive clinical samples. The solid
line represents the Deming regression line. The dashed line is the
line of identitylow-pH sample reduction procedure. The only instru-
ments required are a reverse-phase HPLC column and
pre-column and UV detector, standard equipment in hos-
pital laboratories. Although these features are less import-
ant in a dedicated research or reference laboratory, they
make the method practical for use in an ordinary clinical
laboratory.
The mobile phase is extremely simple, stable and iso-
cratic. This type of mobile phase composition was previ-
ously reported for analyzing vitamin C in green beans
[69], but the procedure had to be modified to account
for the much greater sensitivity required for plasma ana-
lysis, plasma’s much higher protein concentration (which
necessitates a high concentration of the deproteinizing
acid) and the need to separate the analyte peak from uric
acid. (In fact, the uric acid peak is so well separated that
uric acid can be analyzed using this method [62, 66], but it
provides no advantage over the automated analysis rou-
tinely available in clinical laboratories.) The second
major advantage of the present method is the use of
the reducing agent TCEP at very low pH [70, 76],
which allows extremely simple, trouble-free sample
processing and analysis at constant low pH. Other
methods for reducing dehydroascorbic acid to ascor-
bic acid often involve multi-step and potentially
error-prone pH adjustments, perhaps contributing to theFig. 5 Bland-Altman plot of the data in Fig. 4. Average vitamin C is
the sum of the total vitamin C concentrations obtained with the
two methods divided by 2
Table 2 Comparison of HPLC methods for total plasma vitamin C analysis
ECa Other UV methodsb Present UV method
Equipment
Availability Limited Wide Wide
Cost High Moderate Moderate
Maintenance Complex, lengthy Simple Simple
Separation column Dedicated ion-pairing Reverse phase or ion-pairing Reverse phase
Number of reagents 14 3-6 4
Reagent preparation time (h) 4 1.5 1
Number of proceduresc 7 4-6 4
Number of pH adjustments 3 0-2 0
Time prior to sample injection (h)d 4-5 2-3 2
Chromatographic run time (min) 8 2-16 6
pH
Mobile phase 4.8 4.5-5.7 2.7
Low pH throughout procedure No No Yes
aAs described in the Methods section
bAs described in [59, 63, 64]
cPreparation of reagents and mobile phase, pH adjustments and sample handling
dPreparation of mobile phase, system equilibration, reduction reaction and standards and control analysis
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ported with this analysis [44].
The present method agreed closely with the gold-
standard method, EC-HPLC. The Bland-Altman analysis
indicated that, on average, plasma total vitamin C con-
centrations are 3.7 μmol/L higher with the UV method.
This small bias did not exist for concentrations below
the lower limit of the normal range, 28.4 μmol/L, which
are of greatest clinical interest. It is indeterminate
whether the UV method slightly over-estimates plasma
vitamin C concentrations or the EC method slightly un-
derestimates them. This formal comparison between UV
and EC vitamin C detection methods was made on 80
consecutive clinical samples with no samples excluded.
EC-HPLC is widely recommended over UV-HPLC for
plasma vitamin C analysis [46, 49, 51, 56], but direct evi-
dence that supports this recommendation is unavailable.
The only previous direct comparison of EC-HPLC with
UV-HPLC was with regard to ascorbic acid rather than
total vitamin C, it was based on only 27 samples from
healthy individuals, and it lacked a Bland-Altman ana-
lysis [52]. Nevertheless, the close agreement that was re-
ported between EC and UV detection of ascorbic acid,
even at low plasma concentrations, is consistent with
our observations regarding total plasma vitamin C con-
centrations in a much larger number of consecutive clin-
ical samples.
A very recent article describes a UV-HPLC method for
simultaneously determining ascorbic acid and dehy-
droascorbic acid in human plasma [68]. The applicability
of this method to clinical medicine seems doubtful,because its lower limits of detection for ascorbic acid
(11.4 μmol/L) and dehydroascorbic acid (57 μmol/L) are
well above the range of clinical interest. Moreover, it in-
dicates a normal plasma dehydroascorbic acid concentra-
tion of ~ 50 μmol/L [68], despite the heavy preponderance
of evidence that plasma dehydroascorbic acid concentra-
tions seldom exceed 5 μmol/L [77] and under optimum
handling and processing conditions are usually close to
zero [74].
The UV-HPLC method described here has limitations.
We used a standard reverse phase HPLC column (and
precolumn) which demonstrated excellent performance
for more than 1 year during which a large numbers of
samples were injected onto it. In situations in which
large numbers of samples are analyzed, polymeric or
polar embedded reverse phase columns could be consid-
ered, for they are more resistant to long-term degrad-
ation caused by a completely aqueous, highly acidic
mobile phase [56]. Another potential problem is a
greater chance of interference by exogenous molecules
than EC-HPLC [51, 56]. This problem has not been re-
ported during 30 years of UV-based plasma vitamin C
analysis, but hospitalized patients receive many different
drugs. Plasma vitamin C concentrations could be overes-
timated if a small exogenous molecule absorbed UV
light at 245 nm and eluted from the HPLC column at
precisely the same time as ascorbic acid.
Conclusion
In-hospital hypovitaminosis C is highly prevalent, poten-
tially serious, and easily preventable, but most physicians
Robitaille and Hoffer Nutrition Journal  (2016) 15:40 Page 8 of 9remain unaware of it. The unavailability of simple and
reliable plasma vitamin C determinations in hospitalized
patients creates a barrier to medical awareness and in-
vestigation of this potentially important phenomenon.
We describe a method that fulfills these requirements by
making technical improvements to existing UV-HPLC
procedures and demonstrating that the resulting method
performs equivalently to the gold-standard method, EC-
HPLC.
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